@article{5603f449a5a74798ac15d4708e30eb56,
title = "Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply",
author = "Chen, {Li Tzong} and Andrea Wang-Gillam and {Von Hoff}, {Daniel D.} and Eliel Bayever and Bruce Belanger",
note = "Funding Information: L-TC reports funding from Merrimack Pharmaceuticals, during the conduct of the study; and personal fees from PharmaEngine and Baxalta, outside of the submitted work. AW-G reports grants from Newlink, EMD, Pfizer, AstraZeneca, Precision Biological, BioMed Valley, Halozyme, ChemoCentryx, OncoMEd, ADURO, and Millennium; other fees from Pfizer and Merrimack Pharmaceuticals; and grants from Merrimack Pharmaceuticals, Prometheus, and CTI; outside of the submitted work. DDVH reports grants from Merrimack Pharmaceuticals, during the conduct of the study; and personal fees from AlphaMed Consulting, outside of the submitted work. EB is an employee of Merrimack Pharmaceuticals and has a patent (methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan) issued to Merrimack Pharmaceuticals. BB is employed as statistician at Merrimack Pharmaceuticals. ",
year = "2016",
month = may,
day = "14",
doi = "10.1016/S0140-6736(16)30365-8",
language = "English",
volume = "387",
pages = "1997",
journal = "The Lancet",
issn = "0140-6736",
number = "10032",
}